Bruce Morra Email & Phone Number

Park City, Ut

Board Member and Consultant to public and private pharmaceutical, biotechnology, drug delivery, medical device and specialty materials companies.

Rockville, Md

InforMedix was a public medical device company: patient-interactive combination medication adherence and e-diary products. It was transformed into the private AdhereRx Corp. February 2011. I was on the Board until June 2010 and continue to consult for them. My consulting involves providing guidance on strategic direction and major business deals.

Ness Ziona, Israel

SoluBest is a private drug delivery company using smart polymer nanoparticle constructs to improve oral solubility.

Biotech/pharmaceutical company engaged in R&D, production and delivery of therapeutic peptides/proteins. I helped negotiate deal with GlaxoSmithKline for $150 M + royalties.

SCOLR is a specialty pharmaceutical and drug delivery company developing orally delivered drugs and neutraceuticals.

Stepped in as CEO when prior CEO resigned • Initiated and advanced new pharmaceutical licensing negotiations • Developed partnering/profit sharing strategies to generate increased market interest in our products• Evaluated various strategic transactions and partnering opportunities• Reduced burn rate from ongoing expenses

BioPharm Solutions is a company developing sustained-release protein drugs for once/month injectables and implantables. I consulted on a broad range of technical, business and financial issues.

Medical device company developing products for improved safety of healthcare workers and patients.

Turned around faltering businesses (total budget of $25 million, 135 employees) by devising and implementing new strategies to address current market needsDrug Delivery Business: focused on mucosal and oral delivery of small molecules, peptides/proteins and vaccines• Refocused resources within an 18 product pipeline to drive 3 products into phase II clinical trials (West had never gone beyond phase I.) Submitted first formulation for FDA approval (unusually complex, 17 volume ANDA).• Established cooperative teamwork culture between US and UK groups. Rebuilt the US Business Development, Regulatory and Project Management areas. Consummated 10 development/licensing deals.• Orchestrated spin out of the Drug Delivery business to a leading venture capital group, Warburg Pincus.• Pro-forma revenue increase of 300% to $10 million and Operating Profit improvement from -$14 to -$7 million, with inclusion of a deal that was ready to close with an eager licensee, but was aborted by Warburg Pincus.GFI, Clinical Research Organization• Revitalized 80-bed operation via new marketing focus and redeployment of resources. Increased sales 50% to $8.7 million and Operating Profit from -$1.0 to $0.2 million. Positioned business for divestiture.

Start-up companies developing applications including drug delivery, gene therapy and bioartificial livers, as well as consumer & industrial applications, utilizing unique porous polymer microbeads. Board Member and through May, 2002, Acting President, COO and CFO• Created and implemented new strategic focus on value-added biomedical applications. Identified target markets/applications, established positioning and negotiated with potential collaborators.• Signed major licensing deal with Boston Scientific Corp. • Prepared multi-year financial plan. Wrote business plan. Identified and met with potential investors.

Performed stem cell and other cell-based process, device and drug contract research and manufacturing. I helped determine strategic direction and implement plans for corporate partnering. Identified clients and negotiated deals for preclinical, clinical and commercial development.

Develops, manufactures and licenses drug delivery technologies and products, bioresorbable polymers for medical devices. • Founded and managed all aspects of Flamel's U.S. subsidiary.• Key member of the team which completed IPO for the parent company raising $30 million (6/96). Previously attracted $15 million venture capital (6/95). • Directed drug and medical device development from target identification through, clinical and regulatory strategy, cGMP manufacturing, market positioning and partnering. Drug therapeutic areas included cardiovascular, antiviral, and diabetes, using small molecules and proteins. Medical devices included: drug eluding stents, surgical adhesives, urinary incontinence, vascular grafts, wound dressings, post-surgical adhesion prevention, and tissue scaffolding. • Integrated market, financial and competitive scenarios into appropriate business models used for strategic analysis/planning and discussions with the financial community.

$550 million subsidiary of GAF Corp. (specialty chemicals, mineral products, filters, and advanced materials) I had full P&L responsibility for $30 million worldwide liquid bag filtration business having 185 employees, manufacturing facilities in the U.S., Canada, Belgium, Singapore and Brazil, and sales in over 40 countries. Major markets included: chemicals, automotive, paints, pharmaceuticals, food and beverage. Member of ISP Management Council and ISP Operating Committee.• Developed and implemented first strategic plan to position ISP as a global market leader. Initiated and completed major organizational restructuring in both Europe and the U.S. Increased global sales 5.5% and operating profits 23% in one year. Increased U.S. sales 52%, to $2.8 M and operating profit from -$1.1 M to -$0.37 M in one year. • Commercialized new differentiated line of products enabling ISP to enter previously unavailable markets while generating higher gross profit margins.

U.S. arm of $550 million Ausimont NV, a subsidiary of $12 billion Montedison (Italy). Products included various fluoropolymers, fluorinated fluids and specialty catalysts for the wire and cable, chemical processing, semiconductor, medical, automotive and other industries. I formed and managed 2 new groups: 1) Product Managers, Financial Analysts and Advertising;, and 2) Business Development Managers. Negotiated key sales, supply, marketing and manufacturing agreements. Member of the Executive Committee.• Grew sales from $70-80 million to low/mid $100-200 million range, including a $50 million acquisition (Kynar polymers/monomers business from Atochem).• Developed and executed strategic direction, forecasting procedures and inventory planning which helped turn earnings from -$1.6 million to greater than $15 million.• New Business Development group added profits of $1.1 million in 1991 ($3.2 million in 1992).

U.S. arm of $550 million Ausimont NV, a subsidiary of $12 billion Montedison (Italy). Products included various fluoropolymers, fluorinated fluids and specialty catalysts for the wire and cable, chemical processing, semiconductor, medical, automotive and other industries.• Grew WW sales 35% to over $45 million/yr, including 7 new applications and 3 new product introductions.• Established and managed sales/marketing/technical service teams in Europe and Japan to increase international sales 390% (to greater than $8 million/yr).

Ridgefield, Ct

Market Manager (1986-1988): Developed and implemented strategy for engineering plastics (polysulfones and polyarylates) in electronic, molded circuit boards, process equipment, plumbing, energy and lighting markets.Financial/Business Analyst (1984-1986): Developed models for strategic business plans, production plans, budgets and acquisitions. Reported to CFO and VP/GM. Member of the Strategy Board and Operations Team.

Wilmington, De; Parkersburg, Wv

Solved the customer's need for a molded automotive air cleaner, which resulted in $6 million of new business. Increased production efficiencies and commercialized new engineering plastics.

Freiburg, Germany

Electrochemically prepared and characterizing doped polyacetylene and organic cationic radical crystals. Lectured at German Universities and industrial facilities.

Ph.D., Polymer Science & Engingeering

M.B.A.

B.S.E., Chemical Engineering

Magna Cum Laude, McGillicuddy Research Award